Insights

2023 CANTAB Research Grant Winner: Assessment of cognitive function in patients of breast cancer on chemotherapy: A prospective longitudinal study at tertiary care centre in India

/ Insights

We caught up with the 2023 CANTAB® Research Grant Winner, Dr Simran Kaur, from the All India Institute of Medical Sciences, New Delhi, India. She shares with us how the grant will help to non-invasively explore the neural underpinnings to establish state and trait markers in neuropsychiatric and neurodegenerative disorders. I, Dr Simran Kaur sincerely […]

2023 CANTAB Research Grant Winner: Assessment of cognitive function in patients of breast cancer on chemotherapy: A prospective longitudinal study at tertiary care centre in India Read More »

Supporting research into central nervous system (CNS) disorders to improve patient quality of life

/ Insights

by Martina De LilloClinical ScientistCambridge Cognition Disorders of the Central Nervous System (CNS) affect billions of people worldwide (The Lancet Neurology, 2022), representing an important cause of death and disability around the world. Life expectancy has been extended in the last years which has increased the number of brain pathologies related to aging, such as

Supporting research into central nervous system (CNS) disorders to improve patient quality of life Read More »

2023 CANTAB Research Grant: Exploring the role of intermittent exogenous ketosis on physical and mental fatigue during ultra-endurance performance

/ Insights

We caught up with the 2023 CANTAB Research Grant Secondary Award Winner, Louise Engelbrecht, who tells us how the grant will help to provide a better understanding of cognitive function during ultra-endurance performance and the role of ketone ester supplements to retain cognitive function. ​ I was elated when I got the news about receiving

2023 CANTAB Research Grant: Exploring the role of intermittent exogenous ketosis on physical and mental fatigue during ultra-endurance performance Read More »

2023 CANTAB Research Grant: The microbiota-gut-brain axis in young binge drinkers: The interplay between alcohol use, microbiota composition and neurocognitive functioning

/ Insights

We caught up with the 2023 CANTAB™ Research Grant Secondary Award Winner, Eduardo López-Caneda, from the School of Psychology at the University of Minho​who. He shares with us how the grant will help to understand cognitive training and neuromodulation as a potential strategy to modify alcohol consumption habits. I am deeply grateful to Cambridge Cognition

2023 CANTAB Research Grant: The microbiota-gut-brain axis in young binge drinkers: The interplay between alcohol use, microbiota composition and neurocognitive functioning Read More »

Digital Biomarkers & Alzheimer’s Research: Q&A with Liam Kaufman, VP of Clinical Sciences

/ Insights

Kaufman discusses the ways the digital biomarkers are improving Alzheimer’s research by directly tackling some of the unique challenges that researchers face. by Mike HollanOriginally published on PharmExec.com Researching and developing treatments for Alzheimer’s disease comes with unique challenges, due to the nature of the disease. Liam Kaufman, VP of clinical sciences at Cambridge Cognition, spoke

Digital Biomarkers & Alzheimer’s Research: Q&A with Liam Kaufman, VP of Clinical Sciences Read More »

Technology for successful decentralised clinical trials

/ Insights

The landscape of clinical trials is undergoing a profound transformation, one that holds the promise of faster drug development, increased patient participation, and improved data quality.  At the forefront of this revolution stands the concept of Decentralised Clinical Trials (DCTs), a game-changing approach that is reshaping the way we conduct clinical research. In this blog

Technology for successful decentralised clinical trials Read More »

Why don’t we trust people’s lived-experience of fatigue?

/ Insights

Fatigue is the sort of subjective phenomenological experience that has plagued philosophers and neuroscientists for centuries. For those with lived experience, fatigue can be debilitating, and patients can be left feeling ignored and maligned. Despite over 17 million people across Europe1, reporting symptoms of Long Covid, with fatigue being the most common symptom, there is

Why don’t we trust people’s lived-experience of fatigue? Read More »

Speech based biomarkers for monitoring progressive changes in Alzheimer’s disease

/ Insights

A speech based composite which tracks change in AD over time was recently developed and piloted through a collaboration between Winterlight Labs and Genentech.

Speech is a rich source of clinical information when assessing and monitoring Alzheimer’s Disease. Natural language processing technologies, like those developed by Winterlight Labs, can objectively quantify speech and enable its use as a novel endpoint in drug development.

Speech based biomarkers for monitoring progressive changes in Alzheimer’s disease Read More »

The next generation of treatments for Alzheimer’s Disease in clinical trials

/ Insights

The latest advances in the treatment of Alzheimer’s disease and how Cambridge Cognition are designing and implementing empirically validated and clinically-relevant cognitive tasks to help develop the next generation of Alzheimer’s disease treatments. 

There are presently over 140 drugs being explored as possible treatments for Alzheimer’s Disease (AD) in clinical trials. Of these, nearly 80% are intended to slow the progression of AD. Historically, cholinesterase inhibitor drugs such as galantamine, rivastigmine and donepezil have been approved for treatment of AD. These drugs have been shown to mitigate symptoms of AD, such as memory loss, however they are unable to treat the underlying neurobiological cause of the condition. As such, these drugs do not slow AD progression and are not considered a long-term solution in the battle to end the most common form of neurodegenerative disease.

The next generation of treatments for Alzheimer’s Disease in clinical trials Read More »

Highlights from AAIC 2023

/ Insights

The headline from this year’s AAIC in Amsterdam is undoubtedly the announcement of the results of TRAILBLAZER-ALZ-2, a phase 3 trial of Eli Lilly’s new drug Donanemab with 1,800 participants. Donanemab is an antibody-based drug that works by breaking down already-formed amyloid plaques that build up in Alzheimer’s disease (AD), rather than interfering with their production.

Highlights from AAIC 2023 Read More »

Cambridge Cognition
Scroll to Top